Krystal Biotech's phase 3 trial, IOLITE, evaluates KB803 for corneal abrasions in DEB patients, targeting the disease at a ...

New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients ...

Qlaris Bio to showcase promising data on QLS-111, a novel glaucoma treatment, at the 2025 World Glaucoma Congress, ...

FYB203 has been approved by the US FDA and UK Medicines and Healthcare products Regulatory Agency for the treatment ...

ADX-2191 is an investigational drug candidate from Aldeyra, for the treatment of primary vitreoretinal lymphoma (PVRL), a ...

ST-100 shows promise as a fast-acting treatment for dry eye disease, offering rapid relief and unique collagen repair ...

ForSight Robotics secures $125M to advance its robotic surgery platform, targeting cataract procedures and additional ...

Danegaptide is an oral therapy for early treatment of non-proliferative diabetic retinopathy (NPDR) and associated edema.

The ophthalmic drug development industry is undergoing significant transformation, marked by unprecedented advancements in ...

As its director, Manusis outlines the facility’s role in delivering advanced, personalized solutions to improve vision and ...

Patients in Ontario expose illegal user fees for cataract surgeries in private clinics, urging government action to uphold ...

Assistive devices empower patients with central vision loss to regain independence, enhancing daily activities and reducing ...